Skip to content

Delcath Systems DCTH Business Segments

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Product revenue by Product
CHEMOSAT$6.38M+15.4%$6.4M+30.5%$6.14M+52.4%$5.99M+81.6%$5.53M+113%
HEPZATO KIT$84.06M+74.0%$78.84M+144%$73.46M+295%$64.25M+649%$48.32M+2,306%
Number of orphan drug designations granted by FDA by Product
HEPZATO KIT, Doxorubicin4444
HEPZATO KIT, Melphalan20202020
HEPZATO KIT24242424
Operating Lease, Payments by Geography
Ireland$46K+2.2%$46K+7.0%$35K-10.3%$44K+10.0%$45K+36.4%
U.S.$144K-5.3%$144K+20.0%$152K+100%$152K+56.7%$152K+4.8%
Lessee, Operating Lease, Liability, to be Paid by Geography
Ireland$132K-55.1%$175K-47.9%$213K-44.7%$256K-39.5%$294K-33.9%
U.S.$5.05M-10.2%$5.19M-10.0%$5.34M+21.8%$5.48M+85.3%$5.63M+262%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount by Geography
Ireland$4K-78.9%$7K-70.8%$10K-67.7%$14K-64.1%$19K-56.8%
U.S.$1.38M-18.2%$1.45M-17.7%$1.53M+12.9%$1.61M+74.1%$1.68M+257%
Weighted average discount rate - operating leases by Geography
Ireland32%0.0pp32%0.0pp32%0.0pp32%0.0pp32%0.0pp
U.S.32%0.0pp32%0.0pp32%0.0pp32%0.0pp32%0.0pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How does Delcath Systems break its business down?
Delcath Systems (DCTH) reports product revenue by product across 2 parts — CHEMOSAT and HEPZATO KIT. Each is extracted from the segment footnotes and tracked over time.
Where does Delcath Systems's segment data come from?
Segment breakdowns are pulled from the segment footnotes in Delcath Systems's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.